ATE433457T1 - Angiogen-wirkende trisulfat steroide und deren verwendung - Google Patents

Angiogen-wirkende trisulfat steroide und deren verwendung

Info

Publication number
ATE433457T1
ATE433457T1 AT03788740T AT03788740T ATE433457T1 AT E433457 T1 ATE433457 T1 AT E433457T1 AT 03788740 T AT03788740 T AT 03788740T AT 03788740 T AT03788740 T AT 03788740T AT E433457 T1 ATE433457 T1 AT E433457T1
Authority
AT
Austria
Prior art keywords
trisulphate
angiogenic
steroids
compounds
provides
Prior art date
Application number
AT03788740T
Other languages
English (en)
Inventor
Aly Karsan
Michel Roberge
Raymond Andersen
Ingrid Pollet
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE433457T1 publication Critical patent/ATE433457T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064Endothelial cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03788740T 2002-12-24 2003-12-24 Angiogen-wirkende trisulfat steroide und deren verwendung ATE433457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43586402P 2002-12-24 2002-12-24
PCT/CA2003/002024 WO2004058795A1 (en) 2002-12-24 2003-12-24 Angiogenic compounds and uses thereof

Publications (1)

Publication Number Publication Date
ATE433457T1 true ATE433457T1 (de) 2009-06-15

Family

ID=32682287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03788740T ATE433457T1 (de) 2002-12-24 2003-12-24 Angiogen-wirkende trisulfat steroide und deren verwendung

Country Status (7)

Country Link
US (1) US20060014727A1 (de)
EP (1) EP1575981B1 (de)
AT (1) ATE433457T1 (de)
AU (1) AU2003292939A1 (de)
CA (1) CA2508913A1 (de)
DE (1) DE60327946D1 (de)
WO (1) WO2004058795A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8352400B2 (en) 1991-12-23 2013-01-08 Hoffberg Steven M Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore
US7904187B2 (en) 1999-02-01 2011-03-08 Hoffberg Steven M Internet appliance system and method
EP2334686B1 (de) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin-analoga und ihre synthese
EP2421882A4 (de) * 2009-04-22 2013-05-08 Harvard College Angiogenesehemmer
CA2870671C (en) 2012-04-20 2020-05-12 Ohr Pharmaceutical Inc. Aminosteroids for the treatment of a ptp1b associated disease
EA030907B1 (ru) 2013-12-24 2018-10-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
EP3294298A4 (de) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
CN116836215B (zh) * 2023-07-11 2025-10-10 中国药科大学 一种天然产物Sokotrasterol sulfate的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US5079239A (en) * 1990-02-16 1992-01-07 Harbor Branch Oceanographic Institution, Inc. Sterol disulfates and methods of use
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis

Also Published As

Publication number Publication date
CA2508913A1 (en) 2004-07-15
WO2004058795A1 (en) 2004-07-15
EP1575981A1 (de) 2005-09-21
AU2003292939A1 (en) 2004-07-22
US20060014727A1 (en) 2006-01-19
DE60327946D1 (de) 2009-07-23
EP1575981B1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE428428T1 (de) Kombination von azelastine und fluticasone
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
ATE365165T1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60332475D1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE416185T1 (de) Sapogenin derivate, deren synthese und verwendung
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
DE60305200D1 (de) Aminocyclohexylether-verbindungen und deren verwendung
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60327946D1 (de) Angiogen-wirkende trisulfat steroide und deren verwendung
ATE338550T1 (de) Mikronisierter zolpidem hemitartrat
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE60304788D1 (de) Granulatförmige photokatalytische Mischung für Mörtel oder Beton und ihre Verwendung
DK1265911T3 (da) 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
BR0308660A (pt) C-17 espirolactonização e 6,7 oxidação de esteróides
DK1467762T3 (da) Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
NO20033321D0 (no) Androgeniske 7-substituerte 11-halogensteroider
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
CY1106754T1 (el) Σκευασματα τιμπολονης
DE60323513D1 (de) Oberflächenmodifizierte plexifilamentarstrukturen und zusammensetzungen dafür
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
NO20043455L (no) Fremgangsmate for fremstilling av 7alfa-metylsteroider

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties